Navigation Links
Interim Safety Data Favorable for Vical's Phase 2 Trial of DNA Vaccine Against CMV
Date:10/17/2007

omplementary technologies or greater resources. These strategic partnerships provide the company with mutually beneficial opportunities to expand its product pipeline and address significant unmet medical needs. Additional information on Vical is available at http://www.vical.com.

This press release contains forward-looking statements subject to risks and uncertainties that could cause actual results to differ materially from those projected, including: whether the company will successfully enroll 80 matched, related stem cell transplant donor/recipient pairs or 80 additional recipients in a timely manner, if at all; whether the CMV vaccine will achieve the safety and efficacy endpoints in the Phase 2 trial for stem cell transplant donors and/or recipients, including whether the favorable interim safety data are predictive of safety data for the full trial; whether the company will expand development of a CMV vaccine to address prevention of congenital disease; whether the vaccine will induce both antibody and cellular immune responses; whether the vaccine will prevent clinically significant CMV levels; whether Vical or its collaborative partners will seek or gain approval to market any product candidates; whether Vical or its collaborative partners will succeed in marketing any product candidates; and additional risks set forth in the company's filings with the Securities and Exchange Commission. These forward-looking statements represent the company's judgment as of the date of this release. The company disclaims, however, any intent or obligation to update these forward-looking statements.

Contacts: Investors: Media:

Alan R. Engbring Susan Neath

Vical Incorporated Porter Novelli Life Sciences

(858) 646-1127 (619) 849-6007

Website:

SOURCE Vical Incorporated
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related medicine technology :

1. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
2. Positive ZIO-201 Interim Phase II Sarcoma Data Presented at European Society for Medical Oncology
3. Ablynx Announces Interim Results of First Nanobody Phase I Study of ALX-0081 (ANTI-VWF)
4. Based on Up to 6 Years of Follow-Up, Biovest Announces Favorable Interim Blinded Data for Fast-Tracked Pivotal Phase 3 Clinical Trial of BiovaxID Anti-Cancer Vaccine for Non-Hodgkins Lymphoma
5. ZIO-101 (Darinaparsin) Interim Phase II and Preclinical Data Presented at International Myeloma Workshop
6. Accentia Biopharmaceuticals Announces Favorable Interim Blinded Data on SinuNase in Its Fast-Tracked Pivotal Phase 3 Clinical Trial for Chronic Sinusitis
7. Pharmacyclics Announces Interim Results From Two Ongoing Phase 2 Trials Supporting Potential of Xcytrin Plus Chemotherapy to Treat Recurrent Non-Small Cell Lung Cancer
8. Interim Analysis of Crinone Pregnancy Study to Be Published in American Society for Reproductive Medicine Journal
9. Avalon Pharmaceuticals Announces Positive Interim Results For AVN944 Phase I Trial
10. Vical Interim Clinical Results Demonstrate Safety and Tolerability of Inovio Biomedicals Electroporation DNA Delivery Technology
11. Interim Data From RECORD Study Show No Significant Difference Between Avandia and Standard Therapy in Risk of Cardiovascular Hospitalization or Death
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/17/2013)... 17, 2013 Oramed Pharmaceuticals Inc. ... drug delivery systems, announced today that the United States ... Investigational New Drug application(IND) for ORMD-0801, its oral insulin ... the FDA clearance to proceed," stated Nadav ... is a major milestone for Oramed and we look ...
(Date:5/16/2013)... ZURICH , May 17, 2013 ... and Research (A*STAR) and Switzerland,s Cytos ... been dosed in a Phase 1 clinical trial with their ... virus-like particle (VLP) technology. In this first Phase 1 clinical ... and its potential to protect against H1N1 influenza infection will ...
(Date:5/16/2013)...  Nektar Therapeutics, (Nasdaq: NKTR ) President and ... is scheduled to present at the upcoming 2013 UBS Global ... the Sheraton New York Hotel on Tuesday, May 21, 2013 ... be accessible via a Webcast through a link posted in ... http://www.nektar.com . This Webcast will be available for replay ...
Breaking Medicine Technology:Oramed Receives FDA Clearance to Initiate Oral Insulin Trials in the U.S. 2Oramed Receives FDA Clearance to Initiate Oral Insulin Trials in the U.S. 3A*STAR and Cytos Bring Singapore's First Influenza Vaccine to Clinical Testing 2A*STAR and Cytos Bring Singapore's First Influenza Vaccine to Clinical Testing 3A*STAR and Cytos Bring Singapore's First Influenza Vaccine to Clinical Testing 4A*STAR and Cytos Bring Singapore's First Influenza Vaccine to Clinical Testing 5A*STAR and Cytos Bring Singapore's First Influenza Vaccine to Clinical Testing 6Nektar Therapeutics' President and CEO, Howard W. Robin, To Present at the 2013 UBS Global Healthcare Conference in New York City 2
(Date:5/18/2013)... May 18, 2013 MOOSGO.COM published an original ... This book features a group of artists who share their ... photographs, illustrations and paintings. Exclusively for iPad . ... including songs and videos that reflect the signature idiosyncrasy and ... at the Apple iBook Store and it includes a ...
(Date:5/18/2013)... Minn. -- Regular consumption of coffee is associated ... (PSC), an autoimmune liver disease, Mayo Clinic research ... Digestive Disease Week 2013 conference in Orlando, Fla. ... the bile ducts that results in inflammation and ... the liver, liver failure and biliary cancer. , ...
(Date:5/18/2013)... ground-breaking advance in colonoscopy technology signals the future ... at Digestive Disease Week (DDW). Additional research focuses ... and exploring safer methods for removing polyps. ... called a colonoscope to examine the colon. This ... to look for precancerous polyps called adenomas in ...
(Date:5/18/2013)... Coral Springs, FL (PRWEB) May 18, 2013 ... segment dedicated to the special places we call home. These ... found on maps. They are the locations where the people ... The first-rate show takes viewers off the highways and shares ... the best of both nations with an American sports and ...
(Date:5/18/2013)... May 18, 2013 After working diligently for ... SizeItUp formally announced the integration of the fitment specs ... Genesis is set to stun the automobile market with its ... Hyundai Genesis is marked as the latest entry in the ... vehicles lined up for the year 2013. , Aptly ...
Breaking Medicine News(10 mins):Health News:New Art Book for iPad: Tango Art 2Health News:New colonoscope provides ground-breaking view of colon 2Health News:New colonoscope provides ground-breaking view of colon 3Health News:New colonoscope provides ground-breaking view of colon 4Health News:Communities of Distinction TV Presents "A Place to Call Home" Segment 2Health News:Renowned Rim Fitments Provider SizeItUp Launched Database Integrations for the 2012 Hyundai Genesis 2
... continue volunteer relief project for one more month ... On Disaster,Response (HODR), a volunteer-driven 501(c) 3 nonprofit ... volunteer,project in Rayenda, Bangladesh to help those devastated ... Bangladesh in over 15 years, hit the,coastline November ...
... issues of transgender identities -- in the workplace and professional ... vocational counselors to not only treat but to act as ... in the workplace. , "One of the main points of ... be, as vocational psychologists or career counselors, working with transgender ...
... Choices ( http://www.nhs.uk ), the,digital ,front door, to ... aimed to,help people improve their fitness levels., ... http://www.nhs.uk/Livewell/fitness/Pages/fitnesshome.aspx ) enables users,to get the low down ... and,provides them with clinically approved guidance to help ...
... social cues may mimic those of people, scientists say ... have social lives, too, and watching how their brains ... social behavior and autism. , Little is known about ... it to manage behavior, notes a team of researchers ...
... 2008 In workplaces where nurses are bullied, the ... suffers, and the retention of quality nurses becomes difficult. ... Gynecologic, & Neonatal Nursing reviews the psychological and social ... for creating a respectful work environment. , More ...
... of World TB Day 2008 (March 24), the Infectious ... Association (HIVMA) are urging U.S. policymakers to step up ... the disease both at home and abroad. , With ... in detecting new cases on the decline, resources are ...
Cached Medicine News:Health News:Hands on Disaster Response Extends Cyclone Relief Project 2Health News:Counselors should target discrimination and be advocates for transgender clients 2Health News:Counselors should target discrimination and be advocates for transgender clients 3Health News:Monkey Brain Gives Clues to Human Interaction 2Health News:ID, HIV experts urge more resources for TB 2
... The E-Holder™ Platform is designed with ... E-Gel® 96 and E-Gel® 48 gel cassettes ... This allows reproducible placement and loading from ... to make adjustments to the robot loading ...
... electrophoresis into an automated, high-throughput operation with ... system is ideal for analyzing multiple PCR ... Fully automated, robot-compatible, and ready to put ... your high-throughput screening assignments as easy as ...
... the possibility of leakage around glued or bonded ... gel trays meaning you do no have to ... friendliness, the Primo tanks come with built-in leveling ... Gel Systems are designed to be durable and ...
... formed directly on the UV-transparent gel bed using ... it cools, or outside the unit using a ... 7.5cm wide 10cm long. Different colors are offered ... only). Combs and tape are not included. Gel ...
Medicine Products: